Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Summary
Moderna's stock price more than doubled after announcing positive results from a trial of its experimental mRNA vaccine for melanoma, a deadly skin cancer. The vaccine, used with Merck's drug Keytruda, helped prevent the cancer from returning or spreading in high-risk patients after surgery.Key Facts
- Moderna's vaccine trial showed the treatment reduced melanoma recurrence and spread.
- The vaccine tested is called intismeran and is personalized for each patient.
- It was combined with Merck's Keytruda, a cancer immunotherapy drug.
- Moderna’s stock rose 145% to $154.48 after the announcement; Merck’s stock increased by 10.6%.
- The study focused on patients who had surgery to remove melanoma.
- Experts say this is the first study to show this kind of vaccine can reduce risk of melanoma returning or causing death.
- More than 234,000 melanoma cases are expected in the U.S. by 2026.
- Melanoma is a deadly skin cancer that starts in cells that give skin its color.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
